Nine Square Therapeutics

Founded by life sciences venture capital firm ATP and renowned scientists at the University of California San Francisco (UCSF), Nine Square is uniting machine learning-enabled image-based cell profiling, chemistry and computational sciences to develop more effective drugs, faster. We are building a diversified portfolio of first-in class drug candidates for genetically validated targets on the autophagy/lysosomal pathway to overcoming the historical challenges of treating severe neurodegenerative diseases. We are currently advancing multiple programs through preclinical development, with lead optimization efforts underway towards IND-enabling studies.